Skip to content 
GHK-Cu
50 mgGHK-Cu is a copper-binding tripeptide studied in skin, collagen and tissue-remodeling research. The meaning of those findings depends on the material, formulation, route and research model.23
KLOW overview
KLOW Peptide: Ingredients, Benefits & Research
KLOW peptide is the name used for an 80 mg research blend containing GHK-Cu, BPC-157, TB-500 and KPV. This guide explains what is on the label, why the blend draws interest, what published studies say about each ingredient and which questions about benefits and dosage remain open.
The short version
What is KLOW peptide?
KLOW peptide is a commercial name for a four-component peptide blend, not a single peptide or a standardized scientific term. The product reviewed here lists GHK-Cu 50 mg plus 10 mg each of BPC-157, TB-500 and KPV.8 You may also see it called the KLOW blend or KLOW stack. Because the name is seller-defined, the current label matters; another product could use “KLOW” for a different formula.
That distinction is easy to lose when reading about KLOW online. Most benefit claims trace back to research on one ingredient, such as GHK-Cu or KPV. Those papers can explain where an idea came from, but they do not tell us how the four ingredients behave together.
Explore the ingredientsClaims versus evidence
What are the claimed benefits of KLOW peptide?
Interest in KLOW tends to center on recovery, tissue repair, inflammation, skin appearance and gut-related research. The evidence behind those topics is uneven: some ingredients have limited human data in specific settings, while much of the literature comes from cells or animals. None of the cited studies evaluates the exact 80 mg blend.
When a finding sounds promising, look at the material, model and route. A topical study of one ingredient answers a different question from an injection study, an animal experiment or a trial of the finished formula.
Explore KLOW peptide benefits- RecoveryOften linked to BPC-157 and thymosin-related research, which is largely preclinical or does not test the marketed blend.4
- SkinGHK-Cu has topical and laboratory research, including one small randomized study after laser resurfacing. That evidence does not transfer automatically to another formulation or route.3
- InflammationKPV has been studied in cells and mouse models of intestinal inflammation, not in a human KLOW trial.67
- Complete blendNo cited clinical study tests the stated four-component KLOW formula as one product.
The stated 80 mg formula
What is in the KLOW 80 mg blend?
These figures come from the current product listing, not from dosing research. Treat them as label specifications and recheck them whenever the listing or batch changes.
BPC-157
10 mgMost published BPC-157 research is preclinical. A 2025 systematic review included 35 preclinical studies and one retrospective human study, but found no clinical safety data.4
TB-500
10 mgTB-500 naming is not always consistent. FDA identifies it as the LKKTETQ fragment of thymosin beta-4, and findings for the full 43-amino-acid protein should not be assumed to apply to that fragment.15
KPV
10 mgKPV is a tripeptide studied in cell systems and mouse models of intestinal inflammation. Those studies did not test KLOW or establish human outcomes.67
Ingredient studies and blend-level gaps
What does KLOW peptide research actually show?
The literature behind KLOW is best understood as four separate evidence trails. GHK-Cu, BPC-157, thymosin-related peptides and KPV have each been studied in different materials, models and routes. We found no published study of the exact 50/10/10/10 mg combination.
What evidence exists for each KLOW ingredient?
A quick comparison of what was studied, why it matters and what remains unanswered about KLOW.Scroll horizontally to compare every column.
| Ingredient | Evidence examined | Research focus | What remains unanswered | Sources |
|---|---|---|---|---|
| GHK-Cu | A broad review and a randomized topical study of 13 people after laser resurfacing. | Collagen synthesis, tissue remodeling, cell signaling and topical recovery outcomes. | Effects of GHK-Cu in this formula, or the complete blend’s safety or effectiveness. | 2 3 |
| BPC-157 | A 2025 systematic review covering 35 preclinical reports and one small retrospective human study. | Musculoskeletal injury and repair models. | Human efficacy, clinical safety or an effect from the finished four-part blend. | 4 |
| TB-500 | Laboratory research relating shorter sequences to activities associated with full-length thymosin beta-4. | Cell migration, survival and repair-related mechanisms. | That findings for the full protein apply to the listed fragment or to KLOW as a product. | 5 |
| KPV | Cell experiments and two mouse models of intestinal inflammation. | Peptide transport and inflammatory signaling in experimental colitis. | Human outcomes, human exposure safety or an effect from the complete blend. | 6 7 |
| Complete blend | The cited seller label; no blend-level study was identified among the sources reviewed. | The stated four-ingredient formula and the claims attached to it. | Safety, effectiveness, ingredient interactions or a human protocol. | 8 10 |
What about Reddit posts and before-and-after photos?
Reddit threads and before-and-after photos can be useful for finding common questions and reported experiences. They cannot confirm the product, exposure, other changes, photo conditions or what caused a result. FTC guidance is clear that testimonials are not a substitute for scientific evidence.10
KLOW vs GLOW peptide
KLOW vs GLOW peptide: what is the difference?
At the label level, KLOW and GLOW share GHK-Cu, BPC-157 and TB-500. KLOW adds 10 mg of KPV, which raises the stated total from 70 mg to 80 mg.89 The formula comparison is straightforward; an outcome comparison is not. The labels do not show that one blend works better or is safer.
Read the full KLOW vs GLOW comparison
GLOW 70 mg GHK-Cu + BPC-157 + TB-500 View GLOW listing
KLOW 80 mg GHK-Cu + BPC-157 + TB-500 + KPV View KLOW listing
The label-level difference: the cited KLOW formula adds 10 mg KPV.
These commercial links lead to the research-use listings used for the formula comparison. Seller pages document what is claimed on the label; they do not independently verify identity, purity, safety or effectiveness.
Understanding the label
Is 80 mg the KLOW peptide dosage or the vial total?
The 80 mg figure is the total amount the label says is in the vial. It is not an amount per use, a schedule or a preparation method.
Studies of separate ingredients cannot be combined into a validated KLOW peptide dosing schedule. FDA also reports limited safety information for several listed components and says it has not identified human exposure data for KPV or the TB-500 fragment.1
Understand KLOW amounts and unitsResearch purchasing and quality checks
What should you check before buying KLOW peptide?
When evaluating where to buy KLOW peptide for laboratory research, start with the records rather than the headline purity percentage. The product name, four ingredients and lot number should match across the listing, vial and COA. Check who performed the testing, when it was run and which methods were used. FDA’s supplier guidance is written for pharmaceutical compounders, not research-product retailers, but its emphasis on supplier knowledge and valid certificates is a useful quality-control principle.11
A COA is only as useful as the information it contains. Look for the laboratory, analytes, methods, acceptance criteria, units, test date and a matching lot number. One purity percentage does not prove identity, clinical safety or effectiveness.
The current listing also deserves clarification on TB-500 identity. FDA identifies TB-500 as the LKKTETQ fragment, while the seller page displays a different sequence alongside an approximate molecular weight associated with full-length thymosin beta-4.18 Before relying on that specification, request a batch record showing which material was actually tested.
- Lot matchListing, vial and certificate should agree.
- IdentityConfirm the stated material, not only a purity result.
- PurityReview the method, result, laboratory and date.
- LaboratoryIdentify who performed the test, which method was used and when.
Explore by article
Explore KLOW in more detail
KLOW Peptide Research: What the Studies Show
Explore the findings behind KLOW’s ingredients and what each study examined.KLOW Peptide on Reddit: What Users Are Saying
Read community accounts, follow-up comments and the discussions behind them.KLOW Peptide Before and After: A Photo Claim Examined
Look closely at the accounts, photographs and context behind reported changes.KLOW Peptide COA: How to Read the Test Results
Understand batch records, test methods and the details on a certificate of analysis.KLOW Blend Peptide: Ingredients Explained
Explore KLOW’s four ingredients, the 5:1:1:1 ratio and what the 80 mg vial total means.KLOW Peptide Dosage: What Does 80 mg Mean?
Understand the distinction between a vial’s stated content and dosage terminology.Where to Buy KLOW Peptide for Laboratory Research
Explore the supplier listing, batch documentation and purchasing details.KLOW vs GLOW Peptide: What’s the Difference?
Compare the ingredients, stated quantities and the research behind the formulas.KLOW Peptide Benefits: Recovery, Skin and Gut Health
Explore the research and reported experiences behind recovery, skin and gut-related interest.References
Sources for this guide
Citations appear beside the statements they support. FDA and FTC pages provide regulatory and advertising context, journal articles cover ingredient-level research, and seller pages are used only for current label and listing details.
- U.S. Food and Drug AdministrationBulk drug substances that may present significant safety risksView source
- Pickart L, Margolina A. International Journal of Molecular Sciences. 2018.Review of GHK-Cu research themes and mechanismsView source
- Miller TR, et al. Archives of Facial Plastic Surgery. 2006.Randomized topical GHK-Cu study after laser resurfacingView source
- Vasireddi N, et al. Orthopaedic Journal of Sports Medicine. 2025.Systematic review of BPC-157 in orthopaedic sports medicineView source
- Sosne G, et al. FASEB Journal. 2010.Thymosin beta-4 activities defined by shorter sequencesView source
- Dalmasso G, et al. Gastroenterology. 2008.KPV uptake in cells and experimental mouse colitisView source
- Kannengiesser K, et al. Inflammatory Bowel Diseases. 2008.KPV in two murine models of colitisView source
- Pure Lab PeptidesKLOW 80 mg listing and stated compositionView source
- Pure Lab PeptidesGLOW 70 mg listing and stated compositionView source
- U.S. Federal Trade CommissionHealth-products guidance on evidence and testimonialsView source
- U.S. Food and Drug AdministrationSupplier testing, supply-chain transparency and valid COAsView source
Evidence and product details last reviewed September 7, 2026. Listings, batch records and regulatory pages can change, so they are rechecked whenever this guide receives a substantive update.